Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
| Nicox to present at the 2017 BIO International Convention June 15, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Emmet Purtill, Director Business Development, will present at the 2017 BIO International Convention on Thursday June 22 , 2017 at 11:15 a.m. Pacific Time. The conference is being held at the Convention Center in San Diego. The presentation will be available on Nicox website (www.nicox.com) in "Presentations & Events". Mr. Purtill will also be available for one-on-one meetings at the conference. | |
| About Nicox | |
| Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has an approved NDA product and another product at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com . | |
| Analyst coverage | |
| Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France Stifel Christian Glennie London, UK | |
| Upcoming financial and business conferences | |
| September 25-27 Cantor Fitzgerald's 3rd Annual Healthcare Conference New York; US | |
| Contacts | |
| Nicox Gavin Spencer, Executive Vice President Corporate Development T +33 (0)4 97 24 53 00 [email protected] | |
| Investor Relations Europe NewCap Julien Perez, Valentine Brouchot T +33 (0)1 44 71 94 94 [email protected] | Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 [email protected] |
| United States Argot Partners Melissa Forst T +1 (212) 600-1902 [email protected] | France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 [email protected] |
| United States Argot Partners Eliza Schleifstein T +1 (917) 763-8106 [email protected] | |
| Disclaimer | |
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. | |
| Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 | |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6169f64c-7da4-49ca-903d-3c77e19bfcb5
